Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.
暂无分享,去创建一个
F. Mandelli | R. Latagliata | M. Mancini | M. Breccia | G. Alimena | D. Diverio | C. Sarlo | E. Russo | I. Carmosino | F. Biondo | R. D. Cuia | A. D. Vellis
[1] H. Kantarjian,et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α , 2004 .
[2] A. Hochhaus,et al. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance , 2004, Leukemia.
[3] M. Tulliez,et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. , 2003, Blood.
[4] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[5] J. Goldman,et al. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs , 2002, Leukemia.
[6] H. Mano,et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. , 2001, Blood.
[7] J. Topaly,et al. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells , 2001, Leukemia.
[8] E. Macintyre,et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.